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6/j.bThe prognostic relevance of minimal residual disease (MRD) in patients with multiple myeloma is still an open
question. We measured MRD levels in bone marrow (BM) samples of 53 patients treated with high-dose
therapy (HDT) and autologous peripheral blood stem cell transplantation using real-time quantitative
(RQ)-IgH-PCR with allel-specific oligonucleotide probes. We identified a prognostically relevant threshold
level of 0.2% 2IgH/b-actin ratio in the BM before HDT. Twenty-six patients with MRD levels below this value
were termed as the ‘‘low-MRD group,’’ whereas 27 patients with levels above this threshold were allocated to
the ‘‘high-MRD group.’’ Median event-free-survival (EFS) in the low-MRD group was significantly (P 5 .001)
longer than in the high-MRD group with 35 versus 20 months, respectively. Overall survival (OS) within the
low-MRD group was also significantly longer with 70 versus 45 months (P5 .04). Using multivariate analysis,
we found that the pretransplantation MRD level was an independent prognostic factor for EFS (P5.003) and
OS (P5.05). Further, EFS of patients in the high-MRD could be improved (P5.005) when they achieved a low
MRD level after HDT. In conclusion, measuring MRD is of prognostic relevance in patients with MM, and low
MRD levels should be a goal of treatment.
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High-dose chemotherapy (HDT) with autologous
peripheral blood stem cell transplantation (PBSCT)
has improved the survival of patients with multiple
myeloma (MM) [1]. To estimate the prognosis of these
patients, the new international staging system (ISS) [2]artment of Hematology, Oncology and Clinical Im-
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bmt.2011.07.002is commonly used, which relies on cutoff values for
b2-microglobulin and serum albumin. Another rele-
vant prognostic factor is the presence or absence of
cytogenetic aberrations [3]. Still, the results of cytoge-
netic examinations, including classical banding tech-
niques or fluorescence in situ hybridization, are not
available for all patients with MM. A low proportion
of plasma cells in the bone marrow (BM) before
HDT is also reportedly associated with a longer
event-free (EFS) and overall survival (OS) [4]. The
same is true with regard to the achievement of a com-
plete remission, which is defined by the absence of
detectable paraprotein and a negative immunofixation
in the serum and urine [5]. Both parameters are readily
available with the limitation of an analytical sensitivity
of approximately 1022.
Because drugs such as thalidomide [6], bortezomib
[7], or lenalidomide [8] are quite effective and associ-
ated with a considerably higher proportion of patients
with very good partial remission (vgPR) or complete
remission (CR), the detection of minimal residual dis-
ease (MRD) in patients withMMcould be of particular
relevance. Recently, multiparameter flow cytometric423
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and after HDT and autologous PBSCT was a reliable
predictive factor for EFS and OS [9]. Using a limiting
dilution assay for IgH-PCR, Bakkus et al. [10] identi-
fied a threshold level of 0.015% clonotypic cells in BM
samples obtained 3 months after HDT and autologous
PBSCT as prognostically relevant for the EFS. Others
have shown that there is a 0.01% threshold level for
EFS by the simultaneous measurement of MRD in pa-
tient samples with quantitative PCR and flow cytome-
try [11]. Further, the prognostic value of monitoring
MRD by using IgH-PCR could be demonstrated in
the setting of allogeneic transplantation [12] and after
HDT followed by a consolidation therapy including
bortezomib, thalidomide, and dexamethasone [13].
Still, the detection of MRD is no standard method
to estimate the risk of relapse in patients with MM.
Therefore, further studies are needed before results
of MRD may permit therapeutic decisions, as shown
for patients with acute lymphoblastic or chronic mye-
loid leukemia [14].
It is not clear whether the achievement of a molec-
ular remission before HDT is associated with a better
outcome after transplantation. This is of particular
interest with regard to the introduction of new drugs
into the induction therapy before HDT and autolo-
gous PBSCT leading to higher response rates [15].
To address this question, we used real-time quantita-
tive (RQ)-IgH-PCR to evaluate the predictive power
of molecular MRD monitoring before HDT and au-
tologous PBSCT. Further, we investigated whether
a molecular defined remission correlates with the con-
ventional remission status of patients.MATERIALS AND METHODS
Patients and Samples
The 53 patients included in this analysis suffered
from symptomatic MM and received the same first-
line therapy at our hospital. Between November 2000
and October 2007, we treated 121 patients with stage
II/III symptomatic MM with induction chemotherapy
followed by granulocyte-colony stimulating factor
(G-CSF) supported cytotoxicmobilization and a single
HDT with autologous PBSCT. Looking at the entire
group, 80 patients presented with a myeloma subtype
of IgG or IgA qualifying for MRD monitoring using
IgH-PCR. BM samples could be obtained from 70 pa-
tients, and the specific IgH sequence was identified for
55 patients (78%). All patients with a suitable IgH
marker were included in the study regardless of a neg-
ative or positive immunofixation or the remission sta-
tus after HDT. A corresponding IgH-PCR fulfilling
the below defined quality criteria could be established
in 53 patients (76%). In 2 patients, the PCR did not
reach the required sensitivity of at least 1024.The induction treatment of all 53 patients included
in this analysis consisted of 2 to 4 cycles of idarubicine
(20 mg/m2 i.v., days 1-4) and dexamethasone (40 mg
oral, days 1-4, 9-12, 17-21) in monthly intervals.
The patients then received Pegfilgrastim (Amgen,
Munic) or G-CSF in combination with cyclophospha-
mide (2 g/m2, days 112) for PBSC mobilization.
Thereafter, a single HDT was administered at a dose
of 200 mg/m2 melphalan followed by autologous
PBSCT. Approximately 3 months after HDT, all pa-
tients receivedmaintenance therapy with interferon al-
pha (n5 27) or thalidomide (n5 18). In the case of an
HLA-identical sibling donor, an allogeneic transplan-
tation was performed (n 5 8) following reduced-
intensitiy conditioning (RIC) with fludarabine 30
mg/m2 on days 23 to 21 and 2 Gy total body irrida-
tion (TBI) on day 0. Interferon alpha was given at
a dose between 1.0 and 4.5  106 U subcutaneously
twice per week. The daily dose of thalidomide varied
between 100 and 400 mg. Maintenance therapy with
interferon or thalidomide was continued until disease
progression or discontinued in case of toxicity. Remis-
sion status and disease progression were defined ac-
cording to the International Myeloma Working
Group Uniform Response Criteria (IMGW-URC)
[16], with the exception that a complete remission
was not confirmed by BMbiopsy. Because themajority
of patients were treated before 2003, data on the con-
centrations of free-light chains in the serum were not
available. Cytogenetic testing was done by conven-
tional banding metaphase analysis. The median EFS
and OS for the 53 patients were 28 and 61 months, re-
spectively. For patients treated with interferon (IFN)
maintenance, thalidomide maintenance, or RIC allo-
geneic transplantation, the median EFS was 20, 45,
and 25 months, respectively (P 5 .04) and the median
OS was 53, 66, and 40 months, respectively (P 5 .6).
The characteristics of the 53 patients are summarized
in Table 1.
BM samples were obtained at first diagnosis, 2 to
10 days before and 3 to 6 months after HDT and au-
tologous PBSCT. Fifteen patients did not consent to
a third BM puncture after HDT and, therefore, data
of MRD after HDT is only provided for 38 patients.
All patients gave written consent for treatment and
molecular analysis. The study was performed accord-
ing to the guidelines of the ethical committee of the
University of Duesseldorf.Sequencing of the Patient-Specific IgH
Sequence and Real-Time Quantitative IgH-PCR
IgH sequences were derived from total RNA prep-
arations of samples at the time of diagnosis and a
patient-specific RQ-IgH-PCR was performed on the
LightCycler system (Roche, Mannheim, Germany)
using Taqman-technology as previously described
Table 1. Patients’ Characteristics
MRD before Transplantation MRD after Transplantation
All Patients
(n 5 53)
<0.2%
(n 5 26)
>0.2%
(n 5 27) P*
All Patients
(n 5 38)
<0.2%
(n 5 17)
>0.2%
(n 5 21) P*
Age (median years; range) 54 (31-75) 54 (32-69) 54 (31-75) .9 54 (31-75) 54 (42-65) 55 (31-75) .3
Sex (m:f; %) 66:34 58:42 74:26 .3 61:39 53: 47 67:33 .5
Ig subtype (IgG: IgA; %) 77:23 77:23 78:22 1.0 79:21 71:29 86:14 .4
Stage D+S (I + II: III; %) 11:89 12:88 11:89 1.0 16:84 6:94 24:76 .2
Stage ISS (1:2:3; %) 53:34:13 54:35:12 52:33:15 .9 53:37:11 53:35:12 52:38:10 1.0
Cytogenetics (abnormal:normal; %) 26:74 23:77 30:70 .8 21:79 12:88 29:71 .3
Maintenance therapy (IFN:Thal:RIC; %) 49:36:15 54:35:12 44:37:19 .7 47:34:18 41:35:24 52:33:14 .7
Remission before HDT (nCR:PR:MRSD; %) 8:62:30 12:73:15 4:52:44 .1 11:58:32 12:59:29 10:57:33 1.0
Remission after HDT (nCR:PR:MRSD; %) 25:64:11 31:62:8 19:67:15 .5 29:58:13 41:47:12 19:67:14 .3
PC BM infiltration before HDT (<:> 5%; %) 34:66 44:56 24:76 .2 35:65 44:56 29:71 .5
PC BM infiltration after HDT (<:>5%; %) 50:50 56:44 45:55 .7 50:50 67:33 37:63 .2
Salvage therapy with Thal (yes:no; %) 58:42 61:39 56:44 .8 58:42 69:31 50:50 .5
Salvage therapy with Bor (yes:no; %) 49:51 48:52 50:50 1.0 52:48 54:46 50:50 1.0
Salvage therapy with Lena (yes:no; %) 32:68 30:70 33:67 1.0 39:61 31:69 44:56 0.5
BM indicates bone marrow; Bor, bortezomib; f, female; IFN, interferon; HDT, high-dose chemotherapy; ISS, international staging system; m, male; MRD,
minimal residual disease; MRSD, minimal response/stable disease; nCR, near complete remission; PC, plasma cell; PR, partial remission; RIC, reduced-
intensity conditioning allogeneic transplantation; D+S, Durie-Salmon; Thal, thalidomide; Bor, Bortezomib; Lena, lenalidomide.
*Correlations were calculated by the Fisher exact test for 2 categories or by the chi-square test for 3 categories or continous variables.
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following, whereas supplemental information provides
a more detailed description. To achieve optimal spec-
ificity, an allele-specific oligonucleotide (ASO) Taq-
man probe complementary to the CDR3 region, as
well as an ASO sense primer and an ASO antisense
primer, were designed and the IgH-PCR was per-
formed according to the ESG-MRD-ALL guidelines.
Instead of serial dilutions of DNA from the diagnostic
samples with known plasma cell infiltration, a serial
10-fold dilution of 103 to 105 plasmid IgH copy num-
bers was used as an external, exogeneous standard. As
a reference for relative quantification, a b-actin PCR
was run on the same instrument with the same DNA
samples. Each patient-specific PCR reaction required
a minimal sensitivity of 1024 (1025 in 88% of cases)
and a linear amplification within the quantitative range
with r $ .98. To confirm analytical specificity, no
background amplification of each IgH-PCR was
allowed using a pool of DNA from healthy donors.
Negativity was assured by PCR without specific
amplification in 5 replicates, and the proportion of
clonotypic cells among MNCs was expressed as the
2IgH/b-actin ratio in percent.
Determination of a Prognostic Cutoff Value
To preserve sufficient power, the data from
10 patients of our former analysis [17] and another
43 patients observed subsequently were pooled. Deter-
mination of prognostic cutoff points on quantitative
MRD was done in 3 steps: (1) compare the empirical
cumulative distribution functions (ECDF) as cumula-
tive sum percentage curves over the axis of quantitative
MRD values between a positive and a negative out-
come for a statistically significant (P\ .05) difference
with a Kolmogorov-Smirnov test; (2) determine thevalue of quantitative MRD with maximal distance
between the 2 ECDF in any binary endpoint of a signif-
icant Kolmogorov-Smirnov test in step (1); and (3)
determine the cutoff point with a receiver-operating
characteristic (ROC) curve as the value of quantitative
MRDwith amaximalYouden index.As a result, a signif-
icant prognostic threshold level of the 2IgH/b-actin ra-
tio from BM samples before HDT could be defined.
The use of a cutoff value of 0.2% 2IgH/b-actin, as
determined by ROC analysis, resulted in the most
sensitive and specific prognostic estimate (Supplemental
information).
Statistical Analysis
OS andEFS of patients were calculated from the be-
ginning of treatment after first diagnosis and analyzed
by Kaplan-Meier plots and the log-rank test. Correla-
tions between patient characteristics were analyzed
using the Fisher exact test for nominal variables with
2 categories and the 2-sided chi-square test for nominal
variables with 3 categories of continuous variables. Uni-
andmultivariate analyses were performed using the Cox
regression analysis. All patient characteristics with P #
.1 in the univariate analysis and a minimum of
14 patients per group entered the multivariate analysis.RESULTS
MRD Levels Do Not Correlate with
Remission Status
The PCR results from the 53 BM samples col-
lected 1 week before HDT showed a median MRD
ratio of 0.2% 2IgH/b-actin. Nine of the 53 patients
had a negative PCR result, while for the remaining
44 patients the 2IgH/b-actin ratio varied between
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HDT and autologous PBSCT, samples from BM of
38 of the 53 patients were collected 3 to 6 months after
transplantation. The respective median MRD ratio
was 0.3% 2IgH/b-actin. PCR results were negative
for 8 patients, 3 of them with a negative result before
HDT, whereas 30 patients had posttransplantation
MRD values between 0.001% and 21%.
To test whether the MRD level in BM as mea-
sured by RQ-IgH-PCR is a mere molecular correlate
of the IMGW-URC remission status, patients with
a different remission status were compared concern-
ing the 2IgH/b-actin ratio in BM (Figure 1). There
was no correlation of the MRD level before HDT
and autologous PBSCT and the remission status be-
fore transplantation. Similarly, the MRD level after
HDT and autologous PBSCT did not significantly
correlate with the remission status after transplanta-
tion. Therefore, MRD assessment on a molecular
level is a specific measure of residual clonal tumor
cells and differs from the standard evaluation of the
remission status.2I
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Figure 1. The MRD level before (A) or after (B) transplantation does
not correlate with the remission status before or after transplantation,
respectively. Patients with a different remission status were compared
concerning the 2IgH/b-actin ratio in BM. nCR indicates near complete
remission, including complete and very good partial remission;
PR, partial remission; MRSD, minimal response or stable disease.The MRD Level in Bone Marrow before
High-Dose Chemotherapy Is a Prognostic
Parameter for EFS and OS
We looked for a significant prognostic threshold
level of the 2IgH/b-actin ratio fromBMsamples before
HDT.Using ROC analysis with amaximal Youden in-
dex, a cutoff value of 0.2%2IgH/b-actin resulted in the
most sensitive and specific prognostic estimate.
In the next step, we analyzed the EFS andOS of the
patients after allocation to a low-MRD or high-MRD
group, according to the defined cutoff ratio of 0.2%
2IgH/b-actin in the BM before HDT. Of these, 26
were considered to belong to the low-MRD group,
whereas 27 patients were allocated to the high-MRD
group. There were no significant differences between
these 2 groups concerning age, sex, MM subtype, stage
according to Salmon &Durie, ISS stage, cytogenetics,
kind of maintenance therapy, plasma cell infiltration in
the BM, and remission status before or after HDT or
the kind of salvage therapy (Table 1).
Analysis by Kaplan-Meier plots and the log-rank
test showed a difference in the EFS between both
groups of patients. The EFS of patients with MRD ra-
tios of\0.2% 2IgH/b-actin was significantly (P5 .001)
longer than that of patients with MRD ratios of.0.2%
2IgH/b-actin with a median of 35 months and 20
months, respectively (Figure 2A). In the same line, a dif-
ference in theOS between both groups was found. After
a median follow-up of 61 months, patients belonging to
the low-MRDgroup had a significantly (P5 .04) longer
OS with a median of 70 months compared with the pa-
tients of the high-MRD group who had a median OS of
45 months (Figure 2B).TheMRDLevel in BoneMarrow after High-Dose
Chemotherapy Is a Prognostic Parameter for
EFS
Grouping the 38 patients with samples obtained
after HDT and autologous PBSCT on the basis of
an MRD ratio of 0.2% 2IgH/b-actin after HDT re-
sulted in a significantly different median EFS with
32 versus 20months, respectively (P5 .04, Figure 2C).
In contrast, the OS was not significantly different
Figure 2. The MRD levels in BM before (2-10 days) and after (3-6 months) transplantation define groups of patients with different EFS and OS. (A) EFS
and (B) OS of 53 patients allocated to the high or low-MRD group by the cutoff level of 0.2% 2IgH/b-actin ratio in the BM before transplantation were
analyzed by Kaplan-Meier plots and the log-rank test. (C) EFS and (D) OS of 38 patients with MRD levels higher or lower than 0.2% 2IgH/b-actin ratio in
the BM after transplantation, respectively, were similarly analyzed by Kaplan-Meier plots and the log-rank test. (E) EFS and (F) OS was also analyzed
among 21 patients who had high MRD levels before HDTafter allocation with regard to the posttransplantation MRD level.
Biol Blood Marrow Transplant 18:423-431, 2012 427Pretransplantation MRD Level in MMbetween patients allocated on the basis of the post-
transplantation MRD value (P 5 .4, Figure 2D). As
shown in Table 1, there were no significant differences
in the 2 groups concerning patients’ characteristics.
To test whether the posttransplantationMRD level
adds further prognostic information to the pretrans-
plantation MRD level, we analyzed the EFS among
those patients who had high MRD levels before
HDT after allocation with regard to the posttransplan-
tation MRD level (Figure 2E). Those patients whose
MRD levels were reduced to\0.2% 2IgH/b-actin ra-
tio after transplantation had a significantly longer EFS
(P 5 .005) compared with patients who still had MRDlevels above this threshold after transplantation, with
41 versus 14 months, respectively. Still, the OS of these
patients with lowMRD levels after transplantation was
not significantly prolonged (median not reached vs 34
months, P 5 .4, Figure 2F).Uni- and Multivariate Analysis of Predictive
Parameters
Univariate analysis (Table 2) showed that the mo-
lecular cutoff level in BM before (P 5 .002) and after
(P 5 .04) HDT and autologous PBSCT as well as
the kind of maintenance therapy (P 5 .02) were
Table 2. Univariate and Multivariate Analyses for Correlation of Patient Characteristics with EFS or OS
Univariate Analysis
EFS OS
P Value* Hazard Ratio* (95% CI) P Value* Hazard Ratio* (95% CI)
Age (<:> 60 years) .3 1.5 (0.7-2.9) .3 1.7 (0.7-3.9)
Sex (m:f) .8 1.1 (0.6-2.1) .6 1.3 (0.5-3.3)
Ig subtype (IgG:IgA) .5 1.3 (0.6-2.7) .8 1.1 (0.4-2.8)
Stage D+S (I+II:III) .7 1.3 (1.4-3.6) .9 1.1 (0.3-4.7)
Stage ISS (1:2 + 3) .5 1.2 (0.6-2.3) .06 2.3 (1.0-5.4)
Cytogenetics (normal:abnormal) .1 1.7 (0.9-3.4) .001 4.1 (1.8-9.4)
Maintenance therapy (Thal:IFN) .02 2.5 (1.2-5.3) .3 1.6 (0.6-4.6)
Consolidation RIC (yes:no) .7 1.2 (0.5-2.8) .9 1.1 (0.6-1.8)
Remission before HDT (nCR/PR:MRSD) .9 1.1 (0.5-2.1) .3 1.6 (0.6-3.8)
Remission before HDT (nCR:PR/MRSD) .7 1.2 (0.4-4.0) .6 1.4 (0.4-4.8)
Remission after HDT (nCR:PR/MRSD) .3 1.5 (0.7-3.4) .8 1.1 (0.4-3.0)
Remission after HDT (nCR/PR:MRSD) .6 1.3 (0.5-3.6) .1‡ 5.1 (0.7-38.3)
PC BM infiltration before HDT (<:> 5%) .5 1.3 (0.6-2.6) .7 1.2 (0.5-3.0)
PC BM infiltration after HDT (<:> 5%) .5 1.3 (0.6-2.7) .6 1.3 (0.5-3.2)
MRD before HDT (<:> 0.2% IgH/2 b-actin ratio) .002 3.0 (1.5-5.9) .04 2.4 (1.1-5.7)
MRD after HDT (<:> 0.2% IgH/2 b-actin ratio) .04 2.3 (1.0-4.9) .4 1.5 (0.6-3.9)
Multivariate Analysis† EFS OS
P* Hazard Ratio* (95% CI) P* Hazard Ratio* (95% CI)
Cytogenetics (normal:abnormal) .04 4.2 (1.1-16.8)
Maintenance therapy (Thal:IFN) .003 5.1 (1.7-15.2)
MRD before HDT (<:> 0.2% IgH/2 b-actin ratio) .003 4.9 (1.8-13.9)
MRD after HDT (<:> 0.2% IgH/2 b-actin ratio) .007 4.8 (1.5-15.3)
Cytogenetics (normal : abnormal) .003 3.5 (1.5-8.8)
Stage ISS (1:2 + 3) .06 2.3 (1.0-5.6)
MRD before HDT (<:> 0.2% IgH/2 b-actin ratio) .05 2.4 (1.0-5.8)
BM indicates bone marrow; CI, confidence interval; f, female; IFN, interferon; HDT, high-dose chemotherapy; ISS, international staging system; m, male;
MRD, minimal residual disease; MRSD, minimal response/stable disease; nCR, near complete remission; OS, overall survival; PC, plasma cell; PFS,
progression-free survival; PR, partial remission; RIC, reduced-intensity conditioning allogeneic transplantation; D+S, Durie-Salmon; Thal, thalidomide.
Bold 5 significant with p # 0.5.
*Significance of correlation and hazard ratio were calculated by the Cox regression model.
†All patient characteristics with P # .1 in the univariate analysis were included in the multivariate analysis.
‡Remission after HDT (nCR/PR vs MRSD) was not included in the multivariate analysis because of too few patients with minimal response or stable
disease (n 5 6).
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analysis (Table 2), these factors were also independent
factors for EFS (P 5 .003, P 5 .007 and P 5 .003, re-
spectively). Metaphase cytogenetic analysis, which
showed a borderline significance as a prognostic
parameter for EFS in the univariate analysis (P 5 .1),
was also an independent factor by multivariate analysis
(P 5 .04).
With regard to OS, the significant predictive vari-
ables were MRD level in BM before HDT (P 5 .04)
and metaphase cytogenetic results (P 5 .001). Both
factors were independent factors for OS by multivari-
ate analysis (P 5 .05, P 5 .003, respectively).
The cutoff level of 0.2% 2IgH/b-actin in BM be-
fore HDT and autologous PBSCT and metaphase cy-
togenetic results were the only independent factors
predictive for both EFS and OS. The 2IgH/b-actin
threshold ratio therefore adds prognostic information
to established parameters such as ISS stage and cytoge-
netics. This is true not only for patients with good
prognostic parameters, such as low ISS stage and nor-
mal karyotype, but also for patients with poor progno-
sis as defined by a high ISS stage or an abnormal
karyotype (Figure 3). Remarkably, the poor prognosticinfluence of an abnormal karyotype confirmed by
conventional banding analysis was not valid any
longer in 5 patients who achieved a low MRD status
before HDT.DISCUSSION
The results of our study demonstrate the predic-
tive value of molecular MRD monitoring in patients
with MM. On the basis of 53 patients, we could define
a cutoff ratio of 0.2% 2IgH/b-actin in BM before
HDT and PBSCT as a relevant predictive threshold
for the probability of EFS. Patients falling below this
threshold at the time before HDT also had a better
OS than patients with values above this cutoff level.
The MRD level was prognostically independent of
other established prognostic parameters such as ISS
stage or metaphase cytogenetic results. As a conse-
quence, our data imply that a low pretransplantation
MRD level should be a goal for induction treatment.
Our finding that a low MRD level before HDT
and autologous PBSCT is associated with a prolonged
EFS and that patients in the ‘‘poor prognosis’’ group
Figure 3. The pretransplantation MRD cutoff level of 0.2% 2IgH/b-actin ratio is an independent prognostic parameter and provides additional prog-
nostic information to ISS stage and cytogenetics. EFS of patients with high or low MRD levels was separately analyzed for patients with either normal (A)
or abnormal (B) karyotype by Kaplan-Meier plots and log-rank test. Similarly, EFS of patients within the high and lowMRD group was separately analyzed
for patients with either ISS stage 1 (C) or patients with ISS stages 2 or 3 (D).
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2 prognostic groups according to their MRD status
after HDT, are in line with the results of a recent
study using multiparameter flow cytometry for the de-
tection of MRD [9]. In a subgroup analysis by Paiva
et al. [9] 157 patients were evaluated in 3 groups. Pa-
tients who were persistently MRD positive had the
worst prognosis. Patients who were MRD positive
before PBSCT but improved to MRD-negative after
PBSCT had an intermediate prognosis, and patients
who achieved optimal response early and who were
MRD negative before transplantation had the best
prognosis. The MRD threshold level in this study
and another study was 0.01% or lower as determined
by the detection limit of the flow cytometry method
[9,11]. The difference between this cutoff level and
the threshold level of 0.2% in our study is most
likely related to the different techniques of
enumerating clonotypic cells. Keeping in mind that
changes of MRD levels are assessed in log steps, the
threshold level in our study are comparable to other
published data [9-11]. Altogether, our data confirm
the prognostic value of MRD monitoring and
encourage the use of MRD measurement in patients
with MM in the future.From a clinical point of view,MRDresults not only
provide a new independent parameter to assess the
prognosis of patients, but also help us to direct thera-
peutic decisions in the future. Our findings show that
a molecular remission with a pretransplantation
MRD level below 0.2% 2IgH/b-actin is desirable be-
fore the patient receives a HDT. A more intensive in-
duction therapy including thalidomide, bortezomib,
or lenalidomide could be helpful to achieve this
aim [8]. Notably, the data presented here derive from
a treatment strategy with conventional chemotherapy,
and therefore a lowMRD level may only be a surrogate
marker for chemosensitive disease and an effective in-
duction therapy. In the future, it will be interesting to
compare our MRD data from an earlier era of conven-
tional induction chemotherapy with MRD data of
patients receiving novel agents as initial therapy.
Awaiting further evaluation is whether a low level of
MRD following induction therapy with these agents
is still of predictive value. Comparing the MRD level
before and after transplantation favored theMRD level
before HDT as a more significant predictive factor for
OS in our analysis. Notably, this discrepancy was not
related to differences in population selection concern-
ing rescue strategies or other patient characteristics.
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available for the evaluation of theMRD level after HDT
and that deaths occur more rarely than disease progres-
sions, this comparison lacks the necessary statistical
power. Our results ofMRDon amolecular level are per-
fectly in line with clinical data showing that the achieve-
ment of a vgPR to induction treatment was a better
prognostic factor in the IFM 2005-01 trial than vgPR
as the best response after HDT [18].
It was interesting to note that the level of clono-
typic cells was not related to the remission status as
defined by serum electrophoresis, immunofixation,
and the proportion of plasma cells in the BM before
HDT. This is in line with other studies showing no
relationship between the remission status or the num-
ber of plasma cells in the BM and the treatment out-
come of patients [19-21]. Moreover, this finding is
consistent with a recently published comparison of
the remission status as defined by immunofixation,
serum-free light chains, and immunophenotyping. In
this study with 102 patients, the results gained by these
different methods did not correlate, indicating that
these methods provide complementary data [22].
One explanation for the lack of correlation between
a negative MRD determined on a molecular level
and a detectable M-protein in the serum, or even a de-
tectable plasma cell infiltration of the BM, is that the
lifespan of an individual paraprotein varies from pa-
tient to patient, with a range between a few days
and 3 weeks [23]. As a consequence, the paraprotein
is eventually still detectable, whereas the malignant
cell clone is significantly reduced. Moreover, there
are difficulties in discriminating normal or reactive
plasma cells from the malignant cell clone by BM aspi-
ration. Because multiparameter flow cytometric analy-
sis can accurately distinguish between normal and
aberrant plasma cell, the prognostic impact of this
technique is, similar to the PCR-based MRD assess-
ment, superior to the classical evaluations of remission
status [9]. On the other hand, the PCR-based detection
of MRD without overt signs of active disease as as-
sessed by serologic or histologic examination is proba-
bly related to clonal cells without the morphology of a
plasma cell [24-27]. The emergence of such cells may
be a result of changes in the differentiation state or
genetic exchanges between neoplastic and micro-
environmental cells, as already discussed by Ladetto
et al. [13]. Therefore, the molecular assessment of
MRD is not only a very sensitive but also the most spe-
cific method in this context, and thus may add further
information to flow cytometric MRD assessment. A
comparison of MRD results gained by flow and
RQ-PCR on samples of 24 patients showed that both
techniques provide similar prognostic information
[11]. As both methods for MRD assessment detect dif-
ferent target cells, a comparison on a larger number of
patient samples is needed. However, when consideringthe broader availability and limited costs [11], it is
more likely that MRD assessed by flow cytometry
will be the method of choice for routine diagnostics
in the future. Further, it should be considered that
only 53 of our 122 patients had an informative PCR
as a result of the need for a BM sample at the time of
diagnosis and the restriction to patients with a heavy-
chain myeloma subtype. Therefore, molecular MRD
detection will be reserved for special scientific ques-
tions in the future.
In conclusion,MRDdetection by RQ-IgH-PCR is
of prognostic relevance and provides a rationale and
basis for a patient-tailored therapy dependent on the
individual response to a given treatment.ACKNOWLEDGMENTS
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Amplification and Sequencing of the Patient-
Specific IgH Sequence
Mononuclear cells (MNCs) were purified by stan-
dard Ficoll density gradient centrifugation. Genomic
DNA was isolated from BM samples using the
QIAamp Blood Kit (Qiagen, Hilden, Germany), and
total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions.IgH sequences were derived from
total RNA preparations of samples at the time of diag-
nosis. For amplification of the variable region of the
IgH sequence, total RNA was reversely transcribed,
and a consensus PCR was performed with an FR1c
sense primer and JH1245-, JH3- and JH6- antisense
primers (1) using the Gene Amp RNA PCR core kit
(Applied Biosystems, New Jersey). PCR products of
all patients were cloned by ligation to the pCR4-
TOPO plasmid vector and transformation of E.coli
bacteria using the TOPO T/A Cloning Kit for Se-
quencing (Invitrogen, Paisley) according to the manu-
facturer‘s recommendations. Plasmid DNA from 10
bacterial clones of each patient was purified using the
QIAprep Miniprep Kit (Qiagen, Hilden) and se-
quenced by a commercial supplier (SEQLAB,
G€ottingen). A sequence repeated in at least three dif-
ferent clones was considered to be the patient-specific
IgH sequence. The patient-specific complementarity
determining regions (CDR) 1 to 3 were identified by
comparing the IgH sequence to published VH, D and
JH sequences of the V BASE directory (www.mrc-cpe.
cam.ac.uk).
Patient-Specific Real-TimeQuantitative IgH-PCR
The RQ-IgH-PCR was performed on the Light-
Cycler system (Roche, Mannheim) using Taqman-
technology as previously described (2). To achieve
optimal specificity, an allel-specific oligonucleotide
(ASO) Taqman probe complementary to the CDR3
region, an ASO sense primer complementary to the
CDR2 region, and an ASO antisense primer (40% of
patients) complementary to the CDR 3 were designed
with the help of OLIGO 6.0 software or BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) by and pur-
chased from TIB Molbiol (Berlin, Germany). ASO
primers and Taqman probes were complementary to
sequences with a maximum frequency of patient spe-
cific germline IgH mutations and minimal G:C con-
tent. For 60% of patients who had a short CDR3
sequence, an appropriate consensus primer was chosen
as antisense primer.
The IgH-PCR was performed according to the
ESG-MRD-ALL guidelines (3) with some exceptions
as stated below. The reaction was carried out in a final
volume of 20 ml containing 1xLightCycler-FastStartHybridisation Probes Reaction Mix (Roche, Man-
nheim), optimized MgCl2 of 4 to 8 mM dependent
on the target sequence, 0.5 mM of the corresponding
sense and antisense primers, 200 nM ASO Taqman
probe and 1mg of genomic DNA isolated from BM
samples. Cycling conditions were as follows: one cycle
of pre-incubation at 95C for 10 min, 45 cycles of a de-
naturation step at 95C for 15 sec and an amplification
step at 60-67C for 30 sec, one cycle of cooling at
40C for 5 min. LightCycler software was set as fol-
lows: acquisition mode at the end of the amplification:
‘‘single’’, channels: ‘‘F1/F2’’, fluorimeter gains: ‘‘auto-
mated’’. Each run contained a non-template control.
Instead of serial dilutions of DNA from the diagnostic
samples with known plasma cell infiltration as recom-
mended by the ESG-MRD-ALL guidelines, a serial
10-fold dilution of 103 to 105 plasmid IgH copy num-
bers was used as an external, exogeneous standard.
This modification was done due to our previous obser-
vation (2) that the molecular MRD level did not per-
fectly correlate with the proportion of plasma cells
within BM samples. For amplification, linearized plas-
mid DNA was used in the presence of 660ng genomic
DNA pooled from samples of healthy donors, corre-
sponding to approximately 105 cells. The analytical
sensitivity of the reaction was tested for all patients
with a serial 10-fold dilution of the plasmid standard
ranging from theoretically 100 to 105 plasmid copy
numbers. Each patient-specific PCR reaction required
a minimal sensitivity of 1024 (1025 in 88% of cases)
and a linear amplification within the quantitative range
with r $ 0.98. For all patients, the PCR reaction had
a linear analytical sensitivity of # 1024 corresponding
to a quantitative range from 10 clonal cells out of 105
total cells. To confirm analytical specificity, back-
ground amplification of each IgH-PCR was tested
with a pool of DNA from healthy donors. Using the
cycling conditions described above, no background
amplification could be detected for each IgH-PCR.
Positive PCR results were defined by at least one spe-
cific amplification of two replicates, as determined by
the shape of the amplification curve and a CT value
set apart from the background level. Negativity was
assured by PCR without specific amplification in 5
replicates.
As a reference for relative quantification, a ß-actin
PCR was run on the same instrument with the same
DNA samples using the Taqman ß-Actin Control Re-
agents Kit (Applied Biosystems, Foster City) accord-
ing to the manufacturer‘s instructions. Cycling
conditions were identical to those described for the
IgH-PCR.
The IgHand ß-actin copy numberswithin a sample
were calculated from the mean CT values by the use of
the respective standard curve for the IgH- or ß-actin
PCR, respectively. Mean values of the copy numbers
Biol Blood Marrow Transplant 18:423-431, 2012 431.e2Pretransplantation MRD Level in MMfrom two replicates were used and the proportion of
clonotypic cells among MNCs was expressed as the
2IgH/ß-actin ratio in percent. PCR positive results
that were outside the quantitative range and thus not
quantifiable were set to the theoretical minimum
2IgH/ß-actin ratio of 0.001% (1 clonal cell out of
105 total cells). The cut-off level of 0.2% 2IgH/ß-actin
ratio was within the quantitative range of each
IgH-PCR.Determination of a Prognostic Cut-Off Value
Event-free survival and overall survival times were
defined as the time from beginning of treatment after
first diagnosis to the date of disease progression or
death, respectively. To preserve sufficient power, the
data from 10 patients of our former analysis (2) and an-
other 43 patients observed subsequently were pooled.
This does not need any formal statistical adjustment
as the decision to treat more patients did not depend
on the analysis of the first 10 patients.
To estimate the optimal threshold value (cut-off
point) of a diagnostic marker, the Youden index is
commonly used. Therefore, determination of prog-
nostic cut-off points on quantitative MRD was done
in three steps: (i) compare the empirical cumulative
distribution functions (ECDF) as cumulative sum per-
centage curves over the axis of quantitative MRD
values between a positive and a negative outcome for
statistically significant (P\0.05) differencewith aKol-
mogorov-Smirnov test, (ii) determine that value of
quantitative MRD with maximal distance between
the two ECDF in any binary endpoint of a significant
Kolmogorov-Smirnov test in step (i), and (iii) deter-
mine the cut-off point with a receiver-operating
characteristic (ROC) curve as the value of quantitative
MRD with maximal Youden index. Though steps (ii)
and (iii) may give numerically different results, those
values should be very close. Statistical analysis was
done with SAS Statistical Analysis System Software
Version 9.2 (SAS Institute Inc., Cary, NC,USA) under
Windows XP-Professional on an IBM ThinkPad
platform. For step (i), procedure PROCNPAR1WAY
was used which also gives a result for step (ii). The
ROC analysis of step (iii) was then done on the
OUTROC data set created by PROC LOGISTIC.
Results are listed in Table S1 for MRD values before
and after HDT and autologous PBSCT with respect
to two binary endpoints, relapse (yes/no) and death
(yes/no).
Among the 53 patients who entered the study, 40
relapses and 29 deaths were observed during follow-
up. Post-transplantation MRD was available from
only 39 patients among which 29 relapses and 19
deaths were observed. The statistical distributions of
pre- and post-transplantation MRD values were com-
pared between relapsing and non-relapse patients aswell as between follow-up survivors and non-surviving
patients by nonparametric Kolmogorov-Smirnov
tests. While post-transplantation MRD distributions
did not differ statistically, the pre-transplantation
MRD distributions did so between survivors and
non-survivors at nominal significance level of P \
0.05 and – as a borderline result – between relapsing
and non-relapse patients at a nominal significance level
of P 5 0.06 (Table S1).
Sensitivity and specificity estimate from the ROC
analysis translate into proportions of patients with
pre-transplantation MRD . 0.2% 2IgH/ß-actin ratio
among non-survivors, 0.78 (95%ci: 0.56-0.93), and pa-
tients with pre-transplantation MRD # 0.2% 2IgH/
ß-actin ratio among survivors, 0.60 (95%ci: 0.40-
0.78), respectively. From the Kolmogorov-Smirnov
test, the threshold value of 0.12 analogously yields es-
timates of 0.61 (95%ci: 0.38-0.81) and 0.60 (95%ci:
0.40-0.78), respectively.
As prognostic considerations start from classifica-
tion of pre-transplantationMRD, the positive and neg-
ative reverse proportions, calculated as sample
prediction values, are more applicable here: the proba-
bility of later death for patients with pre-transplanta-
tion MRD . 0.2% 2IgH/b-actin is 0.54 (95%ci:
0.33-0.74) and the probability of survival during fol-
low-up for patients with pre-transplantation MRD #
0.2% 2IgH/b-actin is 0.67 (95%ci: 0.46-0.84). The re-
spective results for the threshold of 0.12% 2IgH/b-ac-
tin from the Kolmogorov-Smirnov test are 0.60 (95%
ci: 0.40-0.78) and 0.78 (95%ci: 0.56-0.93) for death
and survival among those surpassing andnot surpassing
that threshold, respectively.
In conclusion, a significant prognostic threshold
level of the 2IgH/ß-actin ratio from BM samples be-
fore HDT could be defined. The use of a cut-off value
of 0.2% 2IgH/ß-actin, as determined by ROC analy-
sis, resulted in the most sensitive and specific prognos-
tic estimate.
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Table S1. Comparison of patients with and without relapse and of surviving and not surviving patients during follow-up by the
respective cumulative percentage curves with a Kolmogorov-Smirnov test, MRD values of maximal distance and of maximal
Youden index.
Kolmogorov-Smirnov test ROC analysis
Test for difference maximal distance maximal Youden index
P value MRD MRD
No. cases/total no. [%2IgH/b-actin] [%2IgH/b-actin]
Relapse
MRD before HDT 40/53 0.06 (0.52)‡ (0.12)‡
MRD after HDT 29/39 0.13 n.a.§ n.a.§
Dead
MRD before HDT 23/53 0.04 0.12 * 0.20 †
MRD after HDT 19/39 0.60 n.a.§ n.a.§
*Sensitivity estimate: 0.6087 (95%ci: 0.38-0.81), specificity estimate: 0.6000 (95%ci: 0.40-0.78).
†Sensitivity estimate: 0.7826 (95%ci: 0.56-0.93), specificity estimate: 0.6000 (95%ci: 0.40-0.78).
‡Values in brackets because of borderline statistical significance at 0.05 < P # 0.10.
§n.a.5 not applicable for more than borderline lack of statistical significance (P > 0.10).
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